Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck

BACKGROUND: Concurrent chemoradiotherapy is an established component of the nonoperative management of locally advanced head and neck squamous cell carcinoma (HNSCC), but the standard dose of 100 mg/m(2) cisplatin every 3 weeks is associated with clinically significant toxicity. Interest in a more t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Natl Cancer Inst
Main Authors: Bauml, Joshua M, Vinnakota, Ravi, Anna Park, Yeun-Hee, Bates, Susan E, Fojo, Tito, Aggarwal, Charu, Limaye, Sewanti, Damjanov, Nevena, Di Stefano, Jessica, Ciunci, Christine, Genden, Eric M, Wisnivesky, Juan P, Ferrandino, Rocco, Mamtani, Ronac, Langer, Corey J, Cohen, Roger B, Sigel, Keith
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510226/
https://ncbi.nlm.nih.gov/pubmed/30239887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djy133
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki